Related references
Note: Only part of the references are listed.Complexity of dopamine metabolism
Johannes Meiser et al.
CELL COMMUNICATION AND SIGNALING (2013)
Istradefylline: First Global Approval
Rosselle Dungo et al.
DRUGS (2013)
Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: A systematic review and meta-analysis
Jie Yang et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Analysis of CYP2D6 genotype and response to tetrabenazine
Raja Mehanna et al.
MOVEMENT DISORDERS (2013)
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective
Marc Maliepaard et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Advances in the genetics of Parkinson disease
Joanne Trinh et al.
NATURE REVIEWS NEUROLOGY (2013)
Pharmacogenomics in early-phase clinical development
Tal Burt et al.
PHARMACOGENOMICS (2013)
Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver
A. Schroeder et al.
PHARMACOGENOMICS JOURNAL (2013)
Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
Howard L. McLeod
SCIENCE (2013)
Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2
Nathan Pankratz et al.
ANNALS OF NEUROLOGY (2012)
Pharmacogenomics in clinical practice and drug development
Andrew R. Harper et al.
NATURE BIOTECHNOLOGY (2012)
Caffeine for treatment of Parkinson disease A randomized controlled trial
Ronald B. Postuma et al.
NEUROLOGY (2012)
Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa
Yoland Smith et al.
NEUROPSYCHOPHARMACOLOGY (2012)
HLA and pharmacogenetics of drug hypersensitivity
Rebecca Pavlos et al.
PHARMACOGENOMICS (2012)
Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database
Christina M. Lill et al.
PLOS GENETICS (2012)
Pharmacogenomics in neurology: Current state and future steps
Andrew Chan et al.
ANNALS OF NEUROLOGY (2011)
Genome-wide association study confirms extant PD risk loci among the Dutch
Javier Simon-Sanchez et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2011)
Global patterns of genetic diversity and signals of natural selection for human ADME genes
Jing Li et al.
HUMAN MOLECULAR GENETICS (2011)
Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease
K. Kalinderi et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2011)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer et al.
NATURE (2011)
Reengineering Translational Science: The Time Is Right
Francis S. Collins
SCIENCE TRANSLATIONAL MEDICINE (2011)
Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee
Taye H. Hamza et al.
PLOS GENETICS (2011)
Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease
Chuong B. Do et al.
PLOS GENETICS (2011)
Tetrabenazine, A Monoamine-Depleting Drug Used in the Treatment of Hyperkinetic Movement Disorders
David R. P. Guay
AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY (2010)
Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
Robert A. Hodgson et al.
EXPERIMENTAL NEUROLOGY (2010)
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury
Jonathan B. Singer et al.
NATURE GENETICS (2010)
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease
Taye H. Hamza et al.
NATURE GENETICS (2010)
Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors
Michael J. Higley et al.
NATURE NEUROSCIENCE (2010)
Novel insights in pharmacogenetics of drug response in Parkinson's disease
Maurits El Arbouw et al.
PHARMACOGENOMICS (2010)
Glutamate, excitotoxicity, and programmed cell death in parkinson disease
W. Michael Caudle et al.
EXPERIMENTAL NEUROLOGY (2009)
Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects
Lisa R. Trevin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Neuroprotection Trials in Parkinson's Disease: Systematic Review
Robert G. Hart et al.
MOVEMENT DISORDERS (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
HLA-B☆5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
Ann K. Daly et al.
NATURE GENETICS (2009)
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Vijayaprakash Suppiah et al.
NATURE GENETICS (2009)
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
NATURE GENETICS (2009)
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease
Wataru Satake et al.
NATURE GENETICS (2009)
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk
Karen M. Powers et al.
MOVEMENT DISORDERS (2008)
Current status of symptomatic medical therapy in Parkinson's disease
Stewart A. Factor
NEUROTHERAPEUTICS (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
HLA-B*5701 screening for hypersensitivity to abacavir
Simon Mallal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis
A. Kindmark et al.
PHARMACOGENOMICS JOURNAL (2008)
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates
Maryka Quik et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future
M Ingelman-Sundberg
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Accelerated evolution of nervous system genes in the origin of Homo sapiens
S Dorus et al.
CELL (2004)
Nicotine enhancement of dopamine release by a calcium-dependent increase in the size of the readily releasable pool of synaptic vesicles
TJ Turner
JOURNAL OF NEUROSCIENCE (2004)
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease
F Bibbiani et al.
EXPERIMENTAL NEUROLOGY (2003)
A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
MA Hernán et al.
ANNALS OF NEUROLOGY (2002)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)